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Abstract Monoclonal antibodies (mAbs), which play a
prominent role in cancer therapy, can interact with specific
antigens on cancer cells, thereby enhancing the patient’s im-
mune response via various mechanisms, or mAbs can act
against cell growth factors and, thereby, arrest the proliferation
of tumor cells. Radionuclide-labeled mAbs, which are used in
radioimmunotherapy (RIT), are effective for cancer treatment
because tumor associated-mAbs linked to cytotoxic radionu-
clides can selectively bind to tumor antigens and release
targeted cytotoxic radiation. Immunological positron emission
tomography (immuno-PET), which is the combination of PET
with mAb, is an attractive option for improving tumor detec-
tion and mAb quantification. However, RIT remains a chal-
lenge because of the limited delivery of mAb into tumors. The
transport and uptake of mAb into tumors is slow and hetero-
geneous. The tumor microenvironment contributed to the lim-
ited delivery of the mAb. During the delivery process of mAb
to tumor, mechanical drug resistance such as collagen distri-
bution or physiological drug resistance such as high intestinal
pressure or absence of lymphatic vessel would be the limited
factor of mAb delivery to the tumor at a potentially lethal mAb
concentration. When α-emitter-labeled mAbs were used,
deeper penetration of α-emitter-labeled mAb inside tumors
was more important because of the short range of the α emit-
ter. Therefore, combination therapy strategies aimed at im-
proving mAb tumor penetration and accumulation would be
beneficial for maximizing their therapeutic efficacy against
solid tumors.
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Introduction
Monoclonal antibodies (mAbs), which play a prominent role
in cancer therapy, can interact with specific antigens on cancer
cells, thereby enhancing the patient’s immune response via
various mechanisms, or mAbs can act against cell growth
factors and, thereby, arrest the proliferation of tumor cells.
Rad ionuc l ide- labe led mAbs, which are used in
radioimmunotherapy (RIT), are effective for cancer treatment
because tumor associated-mAbs linked to cytotoxic radionu-
clides can selectively bind to tumor antigens and release
targeted cytotoxic radiation [1–3]. Iodine-131 (131I)-labeled
mAbs has been widely used in the successful treatment of
patients with lymphoma in nuclear medicine [4–6].
Recently, α-emitter-labeled RIT is considered a promising
therapeutic strategy, because α emitters provide high linear
energy transfer to tumors within a short range [7].
Although the concept of RIT may appear straightforward,
in practice it has been difficult to achieve substantial clinical
success, particularly in solid tumors due to the limited delivery
of mAb into tumor [8, 9]. Furthermore, limited delivery of
mAb would be more problematic in therapy when α-emitter-
labeled RIT was performed because of the short range of α
particles. In this paper, delivery strategies for mAb in RIT, and
the imaging characteristics of some currently and widely used
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radioisotopes such as iodine-124 (124I), zirconium-89 (89Zr),
and copper-64 (64Cu) are discussed. Macro-level and
microcellular-level dosimetry strategies are also described.
Immuno-PET
Immunological positron emission tomography (immuno-
PET), which is the combination of PET with mAb, is an at-
tractive option for improving tumor detection and mAb quan-
tification. Immuno-PET has advantages over conventional
radioimmunoscintigraphy in terms of accurate quantification
of the mAb from the images [10, 11]. The radioisotopes most
often used for immuno-PET are: 64Cu (half-life [t1/2], 12.7 h),
and 124I (t1/2, 4.2 days) [12]. Although
64Cu was widely used
for the clinical imaging of mAb [13, 14], t1/2 of
64Cu is too
short to prove effective with the slow pharmacokinetic profile
of mAb in humans. The accumulation of mAb in tumors is a
slow process, as is their clearance from the blood (t1/2, 50–
90 h) [10]. Slow process of mAb delivery to tumor was due to
limited transport of mAb, which was described in the Blimited
transport of mAb to tumor^ section in detail. Table 1 shows
the physical characteristics of 89Zr, 124I and 18F. PET radionu-
clides with a relatively long t1/2, such as
124I (t1/2, 4.2 days)
and 89Zr (t1/2, 78.41 h), would be more suitable for immuno-
PET than those with a short t1/2.
124I has been used for immuno-PET, but its imaging char-
acteristics are limited in terms of spatial resolution and image
quality. In addition, in vivo dehalogenation of 124I is the main
limiting factor [15]. The spatial resolution of 124I is poorer
than that of 18F, because it has a longer β+ range than that of
18F (β+ range in water, 3.8 and 0.66 mm for 124I and 18F,
respectively). Jin Su Kim’s group in Korea Institute of
Radiological and Medical Sciences (KIRAMS) reported that
the spatial resolution of 124I was reduced by 19 % compared
with that of 18F on the ECAT HR+ scanner. The PET image
quality with this radionuclide is poor owing to the cascade of
γ photons and low β+ branching ratio (β+ branching ratio of
124I, 23 %) [16, 17]. High-energy γ photons (602, 723, and
1691 keV) are emitted in a cascade with the β+ The major
interference is caused by γ photons with energy levels of
602 keV because their energy level falls within the standard
energy window of most PET scanners, which will detect these
photons as additional background noise or interference. In
addition, the 602-keV γ photons have a high branching ratio
of approximately 61 % and, as a result, the dead time of the
system is also increased, while its count-rate performance is
reduced [16]. Cascade γ photons contribute to background
image noise in 124I-PET and, therefore, this background inter-
ference must be corrected to improve the image quality.
Moreover, Preylowski et al. [16] reported that the image qual-
ity could be improved after correcting the background noise
caused by the higher energy γ photons (602 and 732 keV).
The correction of higher energy of γ photons referred to as
Bprompt γ correction^ in the study by Preylowski et al. [16],
was implemented in the Siemens Biograph mCT scanner.
Preylowski et al.’s algorithm calculated the distribution of
prompt coincidence using the convolution prompt γ kernel
with attenuation correction, and for random coincidences it
also corrects acquired data. Kim’s group developed a prompt
γ correction method for 124I-PET in a sinogram space [18].
The fraction of prompt γwas derived using comparison of β+
branching ratio corrected sensitivity. Briefly, the difference
between branching ratio corrected sensitivity of 124I and that
of 18F was a fraction of promptγ [18]. According to the result,
the single γ fraction was 3 % for 350-550 keV, 24 % for 350-
650 keV, and 31 % for 350-750 keV. The higher single γ
fraction for a wider energy window was due to greater inclu-
sion of 602-keV γ within the energy window. Therefore,
background noise count due to higher energy of γ photons
would differ from energy window width. According to the Jin
Su Kim’s method, Bscatter distribution × single γ photon
fraction^ is the portion of background count due to higher
single γ photon which could be calculated using the obtained
scatter sinogram and measured branching ratio corrected sen-
sitivity [18]. Recently, Jin SuKim’s group compared the effect
of different filter and reconstruction methods for 124I quanti-
fication on Siemens Inveon PET scanner [19, 20].
89Zr (t1/2, 78.41 h) is also an ideal radioisotope for immuno-
PET [21–23]. However, 89Zr has also poor imaging character-
istics because of low spatial resolution and image quality. Jin
Su Kim’s group in KIRAMS, Korea, reported that the spatial
resolution of 89Zr was approximately 9 % lower than that of
Table 1 Physical characteristics
of 89Zr, 124I and 18F Properties
89Zr 124I 18F
Half-life 78.4 h 4.18 day 109.8 min
Mean β+ energy 0.40 MeV 0.83 MeV 0.25 MeV
Mean β+ range in water 1.23 mm 3.48 mm 0.62 mm
Single γ energy 909 keV (99.9 %)
1,657 keV (0.1 %)
1,713 keV (0.8 %)
602 keV (61 %)
723 keV (10 %)
1,691 keV (11 %)
β+ branching ratio 23 % 23 % 97 %
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18F was using the Siemens Biograph Truepoint TrueV scanner
(4.5 and 4.1 mm for 89Zr and 18F, respectively) [24]. The
predicted spatial resolution of 124I was 5.5 mm on the
Siemens Biograph Truepoint TrueV scanner [24]. The value
of the β+ range was 1.23, 0.62, and 1.23 mm for 89Zr, 18F, and
124I, respectively. The low spatial resolutions of 89Zr and 124I
were due to their long β+ ranges. The degradation of the
spatial resolution was also observed with animal dedicated
PET scanners. According to the report by Disselhorst’s group,
the spatial resolution of 89Zr was degraded by 10 % compared
with that of 18F on the Siemens Inveon PETscanner (1.99 and
1.81 mm for 89Zr and 18F, respectively) [25]. The β+
branching ratio of 89Zr was 23 %, which is lower than that
of 18F, but similar to that of 124I. Furthermore, the low β+
branching ratio of 89Zr degraded the image quality compared
with that of 18F [24]. Figure 1 shows the transaxial images of
the National Electrical Manufacturers Association (NEMA)
IEC phantom for the comparison of image quality between
89Zr and 18F. In addition, 89Zr emitted 909 keVof γ photons,
which falls outside the energy window of clinical PET scan-
ners, but the associated higher energy is still likely to cause
Compton scattering. Furthermore, there was the possibility
that the scattered photons would be includedwithin the energy
window, and produce some degree of noise [24]. Another
problem associated with the 909-keV energy of γ photons
was the radiation hazard, which was crucial for internal do-
simetry and required the necessary provision of radiation pro-
tection for both patients and workers. Although there were
limitations such as poor spatial resolution and image quality
of the immuno-PET when 89Zr or 124I was used, they were a
suitable match for the t1/2 of the mAb and, therefore, could
provide a tool for monitoring the targeting of mAb to tumors.
Radioimmunotherapy
RIT such as those using 131I tositumomab (Bexxar;
GlaxoSmithKline, Philadelphia,PA, USA) [26–28], 90Y
ibritumomabtiuxetan (Zevalin; Biogen Idec, Cambridge,
MA, USA) [29, 30] and 131I rituximab (Rituxan; Genentech,
South San Francisco, CA, USA) were used for the treatment
of hematological tumors. Recently, 131I tositumomab was
withdrawn for commercial reasons [31]. Regarding RIT for
solid tumors, trastuzumab (Herceptin; F. Hoffmann-La Roche,
Basel, Switzerland), cetuximab (Erbitux; ImClone Systems,
New York, USA), bevacizumab (Avastin; Genentech, South
San Francisco, CA, USA) and panitumumab (Vectibix;
Amgen, Taos, NM, USA) were used for the treatment.
For the RIT, lutetium-177 (177Lu) (t1/2, 6.7 days; Emax,
497 keV; rangemax in water, 2.1 mm), yttrium-90 (
90Y) (t1/2,
2.7 days; Emax, 2,270 keV; rangemax in water, 12.0 mm), and
131I (t1/2, 8 days, Emax, 606 keV, rangemax in water, 2.4 mm)
were used. 90Y is a pureβ emitter, which requires a γ-emitting
surrogate (111In) for clinical imaging [32]. Glatting et al. [33]
and Lhommel et al. [34] reported the feasibility of 90Y as a
PET radionuclide. However, because, the abundance of β+
level of 90Y was extremely low (0.003 %), and
Bremsstrahlung photons were emitted during the PET acqui-
sition [35], PET imaging with 90Y was possibly due to inclu-
sion of Bremsstrahlung photons during PET acquisition. The
90Yparticle has higher energy and longer particle range, lead-
ing to more radioactivity in the tumor cell per peptide mole-
cule and superior crossfire through the tumor, which is espe-
cially advantageous in large tumors and tumors with hetero-
geneous receptor distribution. Furthermore, 177Lu particles
have lower energy and smaller particle range than 90Y does,
leading to better absorption in small tumors [32, 36, 37]. Frost
et al. [32] showed that the mean absorbed dose of 177Lu by the
tumor was more than twofold higher than that for 90Y follow-
ing the administration of the same level of radioactivity.
The use of auger electrons [38–40] or α particles was fea-
sible owing to the high linear energy transfer radiation within
a short range. Alpha particles such as astatine-211 (211At) (t1/2,
7.2 h), bismuth-213 (213Bi) (t1/2, 46 min), actinium-225
(225Ac) (t1/2, 10 days), bismuth-212 (
212Bi) (t1/2, 60 min),
radium-233 (233Ra) (t1/2, 11 days), terbium-149 (
149Tb) (t1/2,
4 h), and fermium-255 (255Fm) (t1/2, 20 h) [41–45] would be
possible for RIT. 211At is of particular interest because of its
high linear energy transfer (5,869 and 7,450MeV α particles),
A B
Fig. 1 Transaxial images of
NEMA IEC phantom using (a)
89Zr images and (b) 18F. Images
were reconstructed using FBP.
This figure is reprinted from Lee
et al. [24]
106 Nucl Med Mol Imaging (2016) 50:104–111
biologically relevant t1/2, and absence of α-emitting daugh-
ters. Auger electron emitting radionuclides that could be used
as theranostic agents are gallium-67 (67Ga), bromine-80m
(80mBr), 89Zr, niobium-90 (90Nb), technetium-99m (99mTc),
indium-111 (111In), tin-117m (117mSn), antimony-119
(119Sb), iodine-123 (123I), iodine-125 (125I), platinum-195m
(195mPt), and thallium-201 (201Tl).
Intranuclear delivery of Auger electron-emitting constructs
results in relative biological efficacy similar to that of α emit-
ters but with a comparatively reduced crossfire effect, making
them more suitable for single-cell irradiation than the α emit-
ters. Auger electron emitters such as 125I have a high linear
energy transfer and short range of emission (<10 μm), making
them suitable for treating micrometastases while sparing nor-
mal tissues [38–40, 46, 47]. In addition, the radiation emitted
during the nuclear decay can be used for imaging either using
SPECTwith γ rays or Bremsstrahlung photons or PET, there-
by rendering Auger-electron-emitting radionuclides as ideal
theragnosis agents [48, 49]. Kiess’s group at John’s Hopkins
University, used a highly specific small molecule targeting the
prostate-specific membrane antigen to deliver 125I to prostate
cancer cells [46]. Hasegawa’s group at the National Institute
of Radiological Science, Japan, reported that 111In
trastuzumab modified with nuclear-localizing signal peptides
efficiently delivered an Auger electron emitter 111In into the
cell nucleus and, therefore, is a promising radiopharmaceuti-
cal in Auger electron RIT suitable for targeted killing of
HER2-positive cancer cells [39].
Falzone’s group at the University of Oxford, UK evaluated
the characteristics of Auger electrons in terms of S values, the
effect of cellular geometry and eccentric cell or nucleus ar-
rangements on S values, dose-point kernels (DPKs), and en-
ergy deposition on a DNA scale compared with an α emitter,
223Ra. The DPK of 223Ra and the Auger electron emitters
showed that with respect to the energy deposited in spheres
of DNA dimensions, only the higher-mass-number Auger
electron emitters deposited comparable amounts of energy.
However, compared with a mono-energetic 5.77-MeV α par-
ticle, the major advantage of Auger electron emitters is that
they have a range of less than 11 nm [48, 50].
Macro-Level and Microcellular-Level Dosimetry
The absorption of energy from ionizing radiation can cause
damage to living tissues, and this effect is used as an advan-
tage in radionuclide therapy. One of the most important factors
in the assessment of the effects of radiation on an organ is the
amount of radiation energy deposited in that organ. The cal-
culation of radiation energy deposited by internal radionu-
clides is the focus of internal radiation dosimetry. Currently,
whole-body dosimetry was used for RIT, and has proven to be
a reliable method for determining the patient-specific maxi-
mally tolerated therapeutic radiation dose required to
maximize efficacy while minimizing organ and bone marrow
toxicity [51, 52]. The Medical Internal Radiation Dosimetry
(MIRD) formulation assumed that radioactivity and energy
was uniformly distributed and deposited within each organ.
This assumption can cause significant errors in the calculated
dose as a result of nonpenetrating radiation (e.g., Auger elec-
trons) when the activity was taken up in specific regions or
cell types within an organ. Therefore, local radionuclide con-
centrations and the subsequently absorbed dose can be much
higher than average calculations of quantities absorbed by
organs might suggest [51]. Dewaraja et al. [53] developed
the patient-specific, three-dimensional (3D) method for
absorbed dose calculation. Although the mean dose estimates
are quite adequate for diagnostic applications, greater accura-
cy is required for therapeutic applications and patient-specific
3D calculations. With the 3D dosimetry, the minimum and
maximum doses, as well as dose nonuniformity can be esti-
mated. Jin Su Kim’s group in KIRAMS, Korea, performed
imaging and therapy using 131I trastuzumab and a pinhole
collimator attached to a conventional gamma camera for hu-
man use in a mouse model. Mouse dosimetry and prediction
of human dosimetry could be used to provide data for the
safety and efficacy of newly developed therapeutic schemes
[54]. Meredith et al. [55] reported the first use of dosimetry in
human α emitter labeled RITwith 212Pb TCMC-trastuzumab.
Tools are needed to visualize and quantify the radioactivity
distribution and absorbed doses to targeted and non-targeted
cells for accurate dosimetry when α-emitter-labeled RIT was
performed [56]. Recently, a single-particle digital autoradiog-
raphy named α camera was developed for the quantification
of α particle for targeted radionuclide therapy. Miller et al.
[56, 57] developed an α camera called the iQID camera,
which is a scintillator-based radiation detection system that
images and identifies α particle emissions spatially and tem-
porally using CCD-CMOS cameras and high-performance
computing hardware. The iQID camera technique was used
for the quantitative imaging of 211At activity distributions in
cryosections of mouse and dog tissue samples [56]. Figure 2.
shows the distribution of 211At 1F5 (anti CD20 mAb) in the
mouse kidney. Frost et al. [58] reported the result of using
211At localization and small-scale dosimetry for optimizing
the mAb dose for 211At RIT using α-imaging systems.
Limited Transport of mAb into Tumor
RIT remains a challenge because of the limited delivery of
mAb into tumors. The transport and uptake of mAb into tu-
mors is slow and heterogeneous [59]. Although, a large
amount of mAb intravenously injected, very little reaches
the tumor and a large portion remains circulating in the plasma
or is taken up even in normal tissues, thereby irradiating and
killing healthy cells over time [60]. Uptaken and penetrated
mAbwas not evenly distributed within the tissue. Monoclonal
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antibodies bind to their targets much faster than they diffuse
through tissue [61]. Only cells adjacent to blood vessels was
more targeted even in well-vascularized regions [62]. The
steps associated with targeting mAb to tumors are blood flow
to the tumor, extravasation across the blood vessel wall, dif-
fusion into the tissue, and binding to the target [61]. Blood
flow occurs in the order of minutes, while binding is complet-
ed in several seconds. While the rates of these processes can
significantly affect the distribution of the mAb in the tumor,
but they do not all have a major impact on the total amount
localized in the tissue [61]. Extravasation across the blood
vessel wall is the rate-limiting step in uptake. Monoclonal
antibodies are transported into tumors by convection and dif-
fusion. Convection of materials in fluids such as mAb in a
tumor occurs by the movement of that liquid. This flow occurs
when there is a difference in pressure, which forces the fluid
from an area of high pressure to that of low pressure. Diffusion
occurs as a result of the random Brownian motion of mole-
cules in a liquid. The distance of mAb diffusion is proportion-
al to the square root of time [59, 62–64].
The time required to deliver mAbs to the tumor vasculature
can be calculated by measuring the blood flow. The time for
blood flow can be calculated as follows
Blood flow time ¼ 1
.
Q 1 – Htð Þ
where Q is the flow rate of the blood in the tumor (volume of
whole blood per volume of tumor per time), and Ht is the
hematocrit. The extravasation rate of mAb is very slow com-
pared with measured flow rates and, therefore, the permeabil-
ity typically has a greater impact on the uptake [60].
The time it takes for the mAbs to penetrate a specified
volume of a tumor is calculated as:
Extravasation time ¼ V
.
PS
where P is the permeability and S/V is the blood vessel surface
area to tumor volume ratio [60].
Convection within the tissue are small compared with the
rate of diffusion and, therefore, diffusive movement mainly
drives the interstitial transport. Using Fick’s law, diffusion




where R is the distance the mAb must diffuse, D is the diffu-
sion coefficient between the cells, and ε is the void fraction
[60].
Extravasation and diffusion were limiting step for delivery
of mAbs. According to the mathematical analysis, estimated
permeability in step of extravasation was 0.003 μm/s for mAb
and 1 μm/s for FDG and diffusion rate was 10 μm2/s for mAb
and 500 μm2/s for FDG [64]. The estimated time-based math-
ematical analysis for delivering the mAb to the tumor was
10 min for convection, 18 h for extravasation, 24 min for
diffusion, and 12 s for binding [59, 60, 64].
Enhancement of mAb Penetration into Tumor
The tumor microenvironment contributed to the limited deliv-
ery of the mAb [65]. The limited targeting and insufficient
dose delivery of mAb to solid tumor were caused by abnormal
structure of tumor vessel, highly fibrotic or desmoplastic tu-
mor, absence of functional lymphatics, and high fluid perme-
ability [59, 66–68]. Tumor cells are surrounded by layers of
extracellular matrix (ECM) proteins (e.g., collagen, elastin,
fibronectin, and laminin), which largely prevents the tumor
vasculature from penetrating the tumor nests. Tumor-derived
ECM plays an important role in inhibiting the penetration and
dispersion of cancer therapeutic agents within tumor masses
and has been implicated in the resistance of solid tumors to
therapy [69]. Beyer et al. [69] observed extensive tumor ECM
and intercellular junctions in patients with breast cancer and in
xenograft models [70].
Targeting tumors with mAb-based therapeutics is a complex
task that presents multiple kinetic barriers. Monoclonal anti-
body internalization and clearance inhibit uptake both in solid
tumors limited by tumor vascular permeability and in
micrometastases limited by diffusion [61, 69]. To improve the
Fig. 2 211At-1F5 (anti-CD20 mAb) micro-biodistribution for the mouse
which was acquired using an α camera. This figure was reprinted from
Miller et al. [56]
108 Nucl Med Mol Imaging (2016) 50:104–111
efficacy of RIT, binding-site barriers need to be surmounted to
enhance the distribution of mAb uniformly in tumors. The
binding-site barriers can cause non-uniform distribution of
mAb in the tumor microenvironment because radiolabeled
mAbs bind primarily to the tumor cells nearest to the vascula-
ture. This hinders the uniform distribution of radiolabeled
mAbs throughout the tumor unless the dose of mAbs adminis-
tered is at a concentration that can saturate all antigens on the
tumor cells. Nonuniform microdistribution of mAb leads to a
marked difference in individual cell survival across the tumor
[71]. Therefore, although RITwas shown to be effective against
hematological tumors, solid tumors were less responsive due to
insufficient dose delivery and radiation resistance [72].
Numerous solutions such as fractionated dosing [73] and
mAb pretargeting methods [74], as well as recombinant
immunotoxins [75], were introduced in attempts to improve
the efficacy of RIT against solid tumors. Yun’s group at
Hanynag University, Korea used ECM-degrading oncolytic ad-
enovirus to achieve a desirable therapeutic outcome in pancre-
atic cancer [76]. Decorin modulates tumor ECM production
and, therefore, has an integral role in the degradation or down-
regulation of tumor ECM constituents or both. The decorin-
based approach would be effective for increasing mAb pene-
tration into solid tumors [69, 77]. Chang H. Paik’s group at
NIH, USA used paclitaxel (Taxol) [8] or pulsed high-intensity
focused ultrasound to enhance the therapeutic efficacy of RIT
against solid tumors [9, 78]. Furthermore, combined RIT strat-
egies could be used to cure solid tumors in patients if the accu-
mulation and penetration of mAb into the tumor microenviron-
ment could be increased, thereby sensitizing more tumor cells
to the radiation from the radiolabeled mAb.
Regarding microcellular level imaging of mAb distribu-
tion, microcellular level studies by Paik et al. [8, 9] showed
the penetration and enhanced accumulation of mAbs in tu-
mors following the modulation of the tumor microenviron-
ment [9, 78]. Although conventional clinical nuclear medicine
imaging techniques such as PET and SPECT have been wide-
ly used in molecular imaging, they have limited spatial reso-
lution for revealing the intratumoral mAb micro-distribution.
Therefore, imaging of fluorescent dye-conjugated mAb distri-
bution would be useful to confirm the micro-distribution of
mAbs within tumors.
Conclusion
The tumor microenvironment may play an important role in
solid tumor RIT. When α-emitter-labeled mAbs were used,
deeper penetration of α-emitter-labeled mAbs inside tumors
was more important because of the short range of the α emit-
ter. Moreover, combination therapy strategies aimed at im-
proving mAb tumor penetration and accumulation are crucial
and would be beneficial for maximizing their therapeutic effi-
cacy against solid tumors.
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